// App-Quantinova.ai

: Late Breaking Abstract - The duration of anti-inflammatory action of fluticasone furoate (FF) assessed via exhaled nitric oxide (FeNO) in asthmatics following administration of FF/vilanterol (VI)

Researchers

Presenter

  • Peter Daley-Yates

Principal Investigators

  • Amanda Baines

  • Kylie Riddell

  • Shashidhar Joshi

  • Philippe Jean Bareille

  • George Bardsley

  • Richard Beasley

  • James Fingleton

Medical Centers

  • GlaxoSmithKline, Uxbridge, United Kingdom

  • GlaxoSmithKline, Stevenage, United Kingdom.

  • Glaxosmithkline, Ermington, Australia

  • Glaxosmithkline, Bangalore, India

  • Medical Research Institute of New Zealand (MRINZ), Wellington, New Zealand

Locations

  • United Kingdom

  • Australia

  • India

  • New Zealand

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • N/A

Drug/Treatment

  • Fluticasone furoate

  • Glucocorticoid

  • Nitric oxide

  • Fluticasone

  • Budesonide

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Cross Over

  • Double Blind/Blinded

  • Controlled

Phase

  • NA

Study Id's

  • NCT02712047

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved